Methods: Descriptive, cross-sectional study. We reviewed the medical records of outpatients with SLE (ACR 1997) who were seen since 2014 to 2016 in the Clinical Hospital of Buenos Aires, Argentina. We evaluated sex, age, disease duration, obstetric history, use and doses of oral corticosteroids, BMI, 25 OH vitamin D and educational level. Disease activity was scored by SLEDAI. Scores ≥4 were classified as active. The patients were classified into 2 groups, according to BMI: normal weight (NW) (19)(20)(21)(22)(23)(24)(25), overweight and obesity (≥25). Results: One hundred and sixty two of 230 were evaluated. Sixty-eight patients were excluded due to lack of data. 157 (97%) were women. Objectives: The aim of the research was to study the processes of formation of antibodies to the enzyme purine metabolism (PM) -xanthine oxidase (XO) and adenosine deaminase (ADA) -in patients with systemic lupus erythematosus (SLE) with laboratory indicants of secondary antiphospholipid syndrome (APS). Methods: 30 healthy people and 60 SLE patients with different clinical manifestations were included in this research. Antibodies to the investigated enzymes were determined in the procedure of an indirect ELISA-test using immobilized form of the corresponding enzyme as antigen array (We have developed this technique). The results of the detection of antibodies to the XO (anti-XO), antibodies to ADA (anti-ADA) and antibodies to the ADC (anti-ADC) were recorded on a spectrophotometer at a wavelength of 450 nm. b 2 -glycoprotein-I-dependent (b 2 GP-I) to the phospholipid antibodies (aPL) class IgM and IgG were determined by using a commercial test kit "Anti-Phospholipid Screen IgG/IgM" (Orgentec). The levels of IgG aPL/IgM did not exceed 10 GPL/MPL-U/ml in the group of healthy individuals. Results: According to the survey the number of SLE patients with elevated levels of anti-ADA was 51.6%, the anti-XO -53.3%. There has been a number of statistically significant correlations between the presence of anti-XO with clinical and laboratory parameters: the level of circulating immune complexes (r=0.297, p=0.024), with a hemoglobin level (r= -0.286, p=0.042), the number of lymphocytes (r= -0.29, p=0.033), and platelets (r= -0,308, p=0.028). In 25 (41.7%) patients with SLE aPL IgG class were detected, in 19 (31.7%) -aPL IgM were detected. As a result of multivariate dispersive analysis leading role of aPL in the development of APS has been established (F=52,5, p<0,001).
Conclusions: Over a half of our cohort had BMI ≥25 and was characterized by older age, more frequent menopause, longer course of the disease, increased steroid use and lower educational level. Depression and hypertension were the statistically more frequent comorbidities found. Obesity was associated with more activity and accrual damage including chronic renal disease. Objectives: The aim of the research was to study the processes of formation of antibodies to the enzyme purine metabolism (PM) -xanthine oxidase (XO) and adenosine deaminase (ADA) -in patients with systemic lupus erythematosus (SLE) with laboratory indicants of secondary antiphospholipid syndrome (APS). Methods: 30 healthy people and 60 SLE patients with different clinical manifestations were included in this research. Antibodies to the investigated enzymes were determined in the procedure of an indirect ELISA-test using immobilized form of the corresponding enzyme as antigen array (We have developed this technique).
The results of the detection of antibodies to the XO (anti-XO), antibodies to ADA (anti-ADA) and antibodies to the ADC (anti-ADC) were recorded on a spectrophotometer at a wavelength of 450 nm. b 2 -glycoprotein-I-dependent (b 2 GP-I) to the phospholipid antibodies (aPL) class IgM and IgG were determined by using a commercial test kit "Anti-Phospholipid Screen IgG/IgM" (Orgentec). Methods: 12 patients with pSS and anxiety disorder (SAS≥50), 11 patients with pSS, and 10 healthy controls were recruited.
(1) Self-rating Anxiety Scale (SAS) were used to assess anxiety level of participations. All the subjects went through functional magnetic resonance imaging (fMRI) while listening actively to neutral words, negative words and negative words alternating with neutral ones. Results: When subjects listened to neutral words alternating with no words, prefrontal cortex and BA21 were active in patients with pSS and anxiety disorder. When subjects listened to negative words alternating with no words, patients showed increased activity in prefrontal cortex, BA21, anterior cingulate and fusiform. Furthermore, when subjects listen to negative words alternating with neutral words, patients with pSS and anxiety disorder showed more increased activity in prefrontal cortex, anterior cingulate, and caudate nucleus than that of other two groups. Conclusions: Anxiety disorder commonly exists in patients with pSS. The pathology of this psychological symptom is poorly understood, which may be one of manifestation of nervous system involvement. fMRI may provide a novel insight into the pathological process accompanying subtle psychiatric disorders commonly experienced by patients with pSS. Background: Up to 50% of systemic lupus erythematosus (SLE) patients experience neuropsychiatric manifestations (NP) during the disease course but many might have subclinical neuropsychiatric lupus (NPL), causing significant increase in morbidity and mortality. The pathogenesis of NPL is multifactorial and involves various inflammatory cytokines, autoantibodies and immune complexes 1 . Objectives: To examine for the presence of subclinical NPL, cerebral atherosclerosis and their correlation -if any to brain magnetic resonance imaging (MRI/MRA) findings and SLE disease activity. Methods: This is a cross sectional observational study that included thirty adult female SLE patients fulfilling the updated ACR classification criteria for SLE 2 . All were subjected to: detailed history taking, thorough clinical examination, assessment of SLE disease activity using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, psychometric evaluations using the Modified MiniMental State Examination (MMSE) to assess for cognitive dysfunction, Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Scale (HAM-A) to assess for the presence of depression and anxiety respectively. CBC, ESR, full blood chemistry, urine analysis, protein/creatinine ratio, brain MRI/MRA. Results: The mean age was 31.7 years (22 to 40 years). 12 patients (40%) had positive antiphospholipid (APL) antibodies with or without clinically evident antiphospholipid syndrome (APS). 22/30 (73.33%) had different NP manifestations, 13 had depression (43.3%), 15 had anxiety (50%) and 16 had cognitive impairment (53.3%). All patients with depression and anxiety, 87.5% of patients with dementia had MRI abnormalities. All SLE patients with positive aPL were found to have MRI abnormalities, while MRI abnormalities were found in only 8 SLE patients with negative aPL (100% vs. 44.4%) (p<0.001). There was a statistically significant correlation between SLE disease activity and both NP manifestations and MRI/MRA abnormalities. aPL antibodies also had a significant correlation with NP manifestations. MRI abnormalities included discrete white matter lesions (60%), cortical atrophy (25%) and gross infarctions (15%). MRA revealed atherosclerotic changes of one or more of the large intracranial vessels in (27.27%) of NPSL patients. Conclusions: Significant number of SLE patients without overt neuropsychiatric manifestations were found to have subclinical cerebrovascular and cognitive dysfunctions, depression and anxiety by simple bedside questionnaires. SLE disease activity positively correlates with neuropsychiatric manifestations. The presence of APL antibodies is a strong risk factor for developing NPSL. Several distinct brain MRI patterns were observed in patients with active NPSL, suggestive of different pathogenetic mechanisms. 
